BioMed Nexus

Stay on the Cutting Edge of Biotech, MedTech, and Pharma.

100% free, unsubscribe anytime.

LATEST ISSUES

BMS Bets $850M on Janux; Corxel’s Massive Series D

BMS Bets $850M on Janux; Corxel’s Massive Series D

Janux secures $850M BMS deal; Corxel raises $287M for oral obesity; Mendra launches with $82M.

IntraBio’s Rare Disease Win & FDA’s New Myeloma Standard

IntraBio’s Rare Disease Win & FDA’s New Myeloma Standard

FDA drafts MRD guidance for myeloma; IntraBio hits Phase 3 endpoints; BioCryst/Astria merger set to close.

Celcuity Secures Priority Review; CRO Consolidation Accelerates

Celcuity Secures Priority Review; CRO Consolidation Accelerates

Gedatolisib earns Priority Review with a July 17 PDUFA date; Worldwide acquires Catalyst amid CRO consolidation. Plus oncology updates and J&J earnings to watch.

Markets Reopen: The $2.5B Supply Test and the J&J Setup

Markets Reopen: The $2.5B Supply Test and the J&J Setup

Absorbing Friday’s Ionis, Blueprint, and Krystal raises, plus what to watch ahead of J&J’s Q4 print on Stelara erosion and MedTech recovery.

The Week Ahead: JNJ, Abbott & the Post-JPM Pivot

The Week Ahead: JNJ, Abbott & the Post-JPM Pivot

Post-JPM reset · $2.5B capital clear-out · JNJ/Abbott earnings setup

JPM Wrap-Up: When Hype Gave Way to Reality

JPM Wrap-Up: When Hype Gave Way to Reality

Financing floods, Sarepta’s reality check, PBMs reposition, and the true cost of capital emerges.